- Home
- SCYX vs XCUR Comparison
SCYX vs XCUR Comparison
Compare SCYX & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCYX | XCUR |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.6M | 26.6M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | SCYX | XCUR |
|---|---|---|
| Price | $0.66 | $4.96 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 563.4K | 43.3K |
| Earning Date | 11-05-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,932,000.00 | N/A |
| Revenue This Year | $167.73 | N/A |
| Revenue Next Year | $290.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.57 | $3.10 |
| 52 Week High | $1.49 | $26.67 |
Technical Indicators
Market Signals| Indicator | SCYX | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 45.86 | 52.56 |
| Support Level | $0.65 | $3.70 |
| Resistance Level | $0.72 | $5.00 |
| Average True Range (ATR) | 0.05 | 0.71 |
| MACD | 0.01 | 0.21 |
| Stochastic Oscillator | 54.91 | 40.29 |
Price Performance
Historical ComparisonAbout SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About XCUR Exicure Inc.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.